COVID-19 Vaccine, mRNA (Pfizer-BioNTech) (Monograph)
Drug class: Vaccines
Warning
National Alert Network (NAN) Alert Regarding Influenza and COVID-19 Vaccine Mix-ups: On October 15, 2021, the NAN issued an alert to make vaccine providers aware of reports of accidental mix-ups between the influenza (flu) and COVID-19 vaccines.600 The alert is based on 16 cases reported to the Institute for Safe Medication Practices (ISMP) error reporting programs.600 Most of the reports ISMP has received involve administration of one of the COVID-19 vaccines instead of an influenza vaccine; in 3 cases, patients received an influenza vaccine instead of a COVID-19 vaccine.600 Because most of the errors were reported by consumers, details about the contributing factors were not provided in many cases.600 However, possible contributing factors include increased demand for vaccination services, the ability to administer the flu and COVID-19 vaccines during the same visit, syringes located next to each other, unlabeled syringes, distractions, and staffing shortages.600 The alert provides recommendations for preventing such vaccine mix-ups. For additional information, consult the NAN alert at [Web].
The American Society of Health-System Pharmacists, Inc. represents that the information provided in the accompanying monograph was formulated with a reasonable standard of care, and in conformity with professional standards in the field. Readers are cautioned that COVID-19 Vaccine (Pfizer-BioNTech) is being investigated for and is currently available under an FDA emergency use authorization (EUA) for active immunization to prevent COVID-19 in those individuals 6 months to 11 years of age. The American Society of Health-System Pharmacists, Inc. makes no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to the information contained in the accompanying monograph, and specifically disclaims all such warranties. Readers of this information are advised that ASHP is not responsible for the continued currency of the information, for any errors or omissions, and/or for any consequences arising from the use of the information contained in the monograph in any and all practice settings. Readers are advised that decisions regarding use of drugs are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and that the information contained in the monograph is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. does not endorse or recommend the use of any drug. The information contained in the monograph is not a substitute for medical care.
Introduction
Nucleoside-modified mRNA (modRNA) vaccine used to stimulate active immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).1 609
Uses for COVID-19 Vaccine, mRNA (Pfizer-BioNTech)
Prevention of Coronavirus Disease 2019 (COVID-19)
Used for active immunization to prevent COVID-19 caused by SARS-CoV-2.1 609
The vaccine labeled as Comirnaty is used for prevention of COVID-19 in individuals ≥12 years of age.1
Although efficacy and safety not definitely established, the Pfizer-BioNTech COVID-19 vaccine is also available under an FDA emergency use authorization (EUA) for prevention of COVID-19 in individuals 6 months through 11 years of age.609
The current COVID-19 vaccine, mRNA (Pfizer-BioNTech) has been specifically formulated for the 2023-2024 season.2 Previous vaccine presentations, which included the intial monovalent formulation (Original strain) and the subsequent bivalent vaccines, are no longer authorized for use in the US; however, evidence of effectiveness and safety of the current vaccine are based principally on data from these previous formulations.1 2 59 68 609
Consult the CDC's Advisory Committee on Immunization Practices (ACIP) interim recommendations and clinical considerations for use of COVID-19 vaccines, including dosage and administration, specific populations and situations, and cautionary information.13
ACIP recommends COVID-19 vaccination in all individuals ≥6 months of age in the US for prevention of COVID-19.13 There is currently no FDA-approved or FDA-authorized COVID-19 vaccine for children <6 months of age. 13 The current ACIP recommendations for COVID-19 vaccinations are available at [Web]
COVID-19 Vaccine, mRNA (Pfizer-BioNTech) Dosage and Administration
General
Pretreatment Screening
-
Screen all individuals for contraindications and precautions to vaccination.13
Patient Monitoring
-
Monitor all individuals who receive a COVID-19 vaccine for immediate adverse reactions according to CDC (ACIP) guidelines.1 ACIP states that vaccination providers should consider observing the following individuals for 30 minutes after receiving the vaccine: those with a history of anaphylaxis to a non-COVID-19 vaccine or injectable therapy; those with an allergy-related contraindication to a different type of COVID-19 vaccine; those with a history of a non-severe, immediate (onset within 4 hours) allergic reaction to a previous dose of COVID-19 vaccine.13 Vaccination providers should consider observing all other individuals for 15 minutes because of the risk of syncope.13
Premedication and Prophylaxis
-
Antipyretics or analgesics (e.g., acetaminophen, nonsteroidal anti-inflammatory agents) may be taken for the treatment of postvaccination local or systemic symptoms, if medically appropriate.13 However, these medications should not be used prophylactically for the purposes of prevention of post-vaccination symptoms.13
-
Premedication with antihistamines prior to vaccination to prevent allergic reactions is generally not recommended; however, while antihistamines will not prevent anaphylaxis, some experts advise antihistamine use as a means of preventing milder allergic reactions in patients who might be at higher risk for allergic reactions.13
Dispensing and Administration Precautions
-
Appropriate medications and supplies for managing immediate allergic reactions must be immediately available in the event that an acute anaphylactic reaction occurs following administration of COVID-19 vaccines.1 13
-
Syncope may occur following administration of parenteral vaccines, especially in adolescents.13 20 Patients should be seated or lying down during vaccination.13 Vaccination providers should consider observing vaccine recipients (especially adolescents) for 15 minutes after vaccination; if syncope develops, patients should be observed until symptoms resolve.13
Administration
IM Administration
Administer only by IM injection.1 609
The Pfizer-BioNTech COVID-19 vaccine is supplied in various formulations and presentations.1 609 There are important differences between these formulations such as method of preparation, requirement for dilution, and storage requirements; consult the manufacturer's labeling (for the Comirnaty product) or the FDA EUA Fact Sheet (for the Pfizer-BioNTech COVID-19 vaccine authorized for use under an EUA) for specific instructions on each formulation.1 609 The various formulations and vial presentations are distinguished by different color vial caps and labels.1 609 As of September 11, 2023, the initial monovalent (Original strain) and bivalent Pfizer-BioNTech COVID-19 vaccine are no longer authorized for use in the US.2
Comirnaty
The COVID-19 vaccine, mRNA (Pfizer-BioNTech)(2023-2024 Formula) labeled as Comirnaty is supplied as a frozen suspension in single-dose vials and prefilled syringes that must be thawed prior to administration; see manufacturer's prescribing information for specific instructions.1 The Comirnaty vaccine does not need to be diluted before use.1
Prior to use of the vial, gently invert 10 times; do not shake.1 The vaccine should appear as a white to off-white suspension; do not use if vaccine is discolored or if particulate matter is observed.1 To administer a dose, withdraw 0.3 mL of the vaccine from the vial using aseptic technique and an appropriate syringe and needle, and administer immediately.1
Do not shake the prefilled syringe prior to use.1 Remove the tip cap and attach a sterile needle to administer a dose.1
Pfizer BioNTech COVID-19 Vaccine (2023–2024 Formula) Vials with Blue Cap
The Pfizer-BioNTech COVID-19 vaccine, mRNA (2023-2024 Formula) authorized for use under an FDA EUA for children 5–11 years of age is supplied in single-dose vials with a blue cap and label.609 The vaccine does notneed to be diluted prior to use.609
Each 0.3 mL dose of the vaccine is formulated to contain 10 mcg of a nucleoside-modified messenger RNA (modRNA) encoding the viral spike (S) glycoprotein of SARS-CoV-2 Omicron variant lineage XBB.1.5 (Omicron XBB.1.5).609
The vaccine is supplied as a frozen suspension that must be thawed prior to use; see EUA fact sheet for specific instructions.609
Prior to use, gently invert the vial 10 times; do not shake.609 The vaccine should appear clear to slightly opalescent with no visible particulates.609 Do not use if liquid is discolored or if particles are observed.609
To administer a dose, withdraw 0.3 mL of the vaccine from the vial using aseptic technique and an appropriate syringe and needle, and administer immediately.609
Pfizer BioNTech COVID-19 Vaccine (2023-2024 Formula) Vials with Yellow Cap
The Pfizer-BioNTech COVID-19 vaccine (2023–2024 Formula) authorized for use under an FDA EUA for children 6 months through 4 years of age is supplied in multiple-dose vials with a yellow cap and label.609 Dilution is required prior to administration.609
Each 0.3 mL dose is formulated to contain 3 mcg of nucleoside-modified messengerRNA (modRNA) encoding the viral spike (S) glycoprotein of SARS-CoV-2 Omicron variant lineage XBB.1.5 (Omicron XBB.1.5). 609
The multiple dose vials contain a frozen suspension that must be thawed prior to administration; see EUA fact sheet for specific instructions.609
Prior to dilution, gently invert the vial 10 times; do not shake.609 Using aseptic technique, dilute the vaccine with 1.1 mL of 0.9% sodium chloride injection.609 The vaccine should appear clear to slightly opalescent with no visible particulates.609 Do not use if liquid is discolored or if particles are observed.609
To administer a dose, withdraw 0.3 mL of the vaccine from the vial using aseptic technique and an appropriate syringe and needle, and administer immediately.609 If the amount of vaccine remaining in the vial cannot provide a full dose of 0.3 mL, discard the vial and any excess volume.609
Dosage
Pediatric Patients
Prevention of COVID-19
Adolescents ≥12 Years of Age
IMUnvaccinated:Administer a single 0.3 mL dose (Comirnaty, gray caps).1 13
Previously vaccinated with 1 or more doses of any mRNA vaccine or Novavax or Janssen COVID-19 vaccine (including in combination with any original monovalent or bivalent COVID-19 vaccine doses): Administer a single 0.3 mL dose (Comirnaty, gray caps).1 13
Administer the updated 2023-2024 vaccine at least 2 months after the last dose of a COVID-19 vaccine for previously vaccinated individuals.1 13
Children 5-11 Years of Age
IMUnvaccinated: Administer a single 0.3 mL dose (Pfizer-BioNTech 2023-2024 Formula, blue caps).13 609
Previously vaccinated with 1 or more doses of any mRNA vaccine: Administer a single 0.3 mL dose (Pfizer-BioNTech 2023-2024 Formula, blue caps).13 609
Administer the updated 2023-2024 vaccine at least 8 weeks after the last dose of mRNA COVID-19 vaccine for previously vaccinated individuals.13 609
Children 6 Months through 4 Years of Age
IMUnvaccinated: Administer 3 doses, 0.3 mL each (Pfizer-BioNTech 2023-2024 Formula, yellow caps); dose 1 and 2 should be given 3–8 weeks apart, and dose 3 should be given at least 8 weeks after dose 2.13 609 For children turning from 4 to 5 years of age during the initial vaccination series, refer to ACIP recommendations at [Web].13
Previously vaccinated with 1 dose of original monovalent or bivalent Pfizer-BioNTech COVID-19 vaccine: Administer 2 doses, 0.3 mL each (Pfizer-BioNTech 2023-2024 Formula, yellow caps); dose 1 should be administered 3–8 weeks after receipt of the last dose of Pfizer-BioNTech COVID-19 vaccine, and dose 2 should be administered at least 8 weeks after dose 1.13 609
Previously vaccinated with 2 or more doses of original monovalent or bivalent Pfizer-BioNTech COVID-19 vaccine: Administer a single 0.3 mL dose (Pfizer-BioNTech 2023-2024 Formula, yellow caps) at least 8 weeks after receipt of the last dose of Pfizer-BioNTech COVID-19 vaccine.13 609
Per FDA authorization, all COVID-19 vaccine doses in this age group should ideally be from the same manufacturer.13
Immunocompromised Children 6 Months through 4 Years of Age
IMUnvaccinated:Administer a 3-dose series, each dose 0.3 mL (Pfizer-BioNTech 2023-2024 Formula, yellow caps).13 609 Dose 1 and 2 should be given 3 weeks apart, and dose 3 should be given at least 8 weeks after dose 2.13 609 For children turning from 4 to 5 years of age during the initial vaccination series, refer to ACIP recommendations at [Web].13
Previously vaccinated with 1 or 2 dose(s) of original or bivalent Pfizer-BioNTech COVID-19 vaccine: Complete the 3-dose series with two or one 0.3 mL dose(s) (Pfizer-BioNTech 2023-2024 Formula, yellow caps), respectively, using the same dosing interval as above.13 609
Previously vaccinated with 3 or more doses: Administer a single 0.3 mL dose (Pfizer-BioNTech 2023-2024 Formula, yellow caps) at least 8 weeks following the last dose. 13 609
One or more additional doses may be administered based on clinicial discretion.13
Per FDA authorization, all COVID-19 vaccine doses in this age group should ideally be from the same manufacturer.13
Immunocompromised Children 5-11 Years of Age
IMUnvaccinated: Administer a 3-dose series, each dose 0.3 mL (Pfizer-BioNTech 2023-2024 Formula, blue caps); ideally all doses from the same manufacturer.13 609 Dose 1 and 2 should be given 3 weeks apart, and dose 3 should be given at least 4 weeks after dose 2.13 609 For children turning from 11 to 12 years of age during the initial vaccination series, refer to ACIP recommendations at [Web].13
Previously vaccinated with 1 or 2 dose(s) of original or bivalent Pfizer-BioNTech COVID-19 vaccine: Complete the 3-dose series with two or one 0.3 mL dose(s) (Pfizer-BioNTech 2023-2024 Formula, blue caps), respectively; ideally from the same manufacturer, using the same dosing interval as above.13 609
Previously vaccinated with 3 or more doses of any mRNA vaccine: Administer a single 0.3 mL dose (Pfizer-BioNTech 2023-2024 Formula, blue caps) at least 8 weeks after the last COVID-19 vaccine dose.13 609
One or more additional doses may be administered based on clinician discretion.13
Immunocompromised Adolescents ≥12 Years of Age
IMUnvaccinated: Administer a 3-dose series, each dose 0.3 mL (Comirnaty, gray caps); ideally all doses from the same manufacturer.1 13 Dose 1 and 2 should be given 3 weeks apart, and dose 3 should be given at least 4 weeks after dose 2.1 13
Previously vaccinatedwith 1 or 2 doses of original monovalent or bivalent Pfizer-BioNTech COVID-19 vaccine: Complete the 3-dose series with two or one 0.3 mL dose(s)(Comirnaty, gray caps), respectively; ideally from the same manufacturer, using the same dosing interval as above.1 13
Previously vaccinated with 3 or more doses of any mRNA vccine or 1 or more doses of Novavax or Janssen COVID-19 vaccine (including in combination with any original monovalent or bivalent COVID-19 vaccine doses): Administer a single 0.3 mL dose (Comirnaty, gray caps) at least 8 weeks after the last COVID-19 vaccine dose.1 13
Adolescents ≥12 years of age who are moderately or severely immunocompromised may receive 1 additional dose of any updated (2023–2024 Formula) COVID-19 vaccine (i.e., Moderna, Novavax, Pfizer-BioNTech) at least 2 months after the last dose of updated (2023–2024 Formula) COVID-19 vaccine.13 Further additional doses may be administered based on clinical judgement.13 Any further additional doses should be administered at least 2 months after the last updated (2023–2024 Formula) COVID-19 vaccine dose.13
Adults
Prevention of COVID-19
IM
Unvaccinated:Administer a single 0.3 mL dose (Comirnaty, gray caps).1 13
Previously vaccinated with 1 or more doses of any mRNA vaccine or Novavax or Janssen COVID-19 vaccine (including in combination with any original monovalent or bivalent COVID-19 vaccine doses): Administer a single 0.3 mL dose (Comirnaty, gray caps). 1 13
Administer the updated 2023-2024 vaccine at least 2 months after the last dose of a COVID-19 vaccine for previously vaccinated individuals.1 13
Adults ≥65 years of age: Administer 1 additional dose of any updated (2023-2024 formula) COVID-19 vaccine (i.e., Moderna, Novavax, Pfizer-BioNTech) at least 4 months following the previous dose of an updated COVID-19 2023–2024 vaccine.13 If Pfizer-BioNTech is used, administer a 0.3 mL dose.13
Immunocompromised Adults:
Unvaccinated:Administer a 3-dose series, each dose 0.3 mL (Comirnaty, gray cap); ideally all doses from the same manufacturer.1 13 Dose 1 and 2 should be given 3 weeks apart, and dose 3 should be given at least 4 weeks after dose 2.1 13
Previously vaccinatedwith 1 or 2 doses of original monovalent or bivalent Pfizer-BioNTech COVID-19 vaccine: Complete the 3-dose series with two or one 0.3 mL dose(s) (Comirnaty, gray caps), respectively; ideally from the same manufacturer, using the same dosing interval as above.1 13
Previously vaccinated with 3 or more doses of any mRNA vaccine or 1 or more doses of Novavax or Janssen COVID-19 vaccine (including in combination with any original monovalent or bivalent COVID-19 vaccine doses): Administer a single 0.3 mL dose (Comirnaty, gray caps) at least 8 weeks after the last COVID-19 vaccine dose. 1 13
Adults up to 64 years of age who are moderately or severely immunocompromised may receive 1 additional dose of any updated (2023–2024 Formula) COVID-19 vaccine (i.e., Moderna, Novavax, Pfizer-BioNTech) at least 2 months after the last dose of updated (2023–2024 Formula) COVID-19 vaccine.13 Further additional doses may be administered based on clinical judgement.13 Any further additional doses should be administered at least 2 months after the last updated (2023–2024 Formula) COVID-19 vaccine dose.13
Adults ≥65 years of age who are moderately or severely immunocompromised should receive 1 additional dose of any updated (2023–2024 Formula) COVID-19 vaccine (i.e., Moderna, Novavax, Pfizer-BioNTech) at least 2 months after the last dose of updated (2023–2024 Formula) vaccine.13 Further additional doses may be administered based on clinical judgement.13 Any further additional doses should be administered at least 2 months after the last updated (2023–2024 Formula) COVID-19 vaccine dose.13
Cautions for COVID-19 Vaccine, mRNA (Pfizer-BioNTech)
Contraindications
-
-
Known history of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine.1
ACIP considers the following to be contraindications to vaccination with both mRNA COVID-19 vaccines (Pfizer-BioNTech COVID-19 vaccine and Moderna COVID-19 vaccine):
-
Warnings/Precautions
Hypersensitivity Reactions
Severe allergic reactions including anaphylaxis reported rarely outside of clinical trials.1 3 13 17 22 23 26 37 40
Delayed-onset local reactions (e.g., erythema, induration, pruritus, tenderness) around the injection site area reported in some vaccine recipients.13 38 ACIP states that delayed-onset local reaction after the first dose of an mRNA COVID-19 vaccine is not a contraindication or precaution to administration of a second dose.13
If a hypersensitivity reaction occurs following COVID-19 vaccination, report the case to VAERS.13
History of severe allergic reaction (e.g., anaphylaxis) after a previous dose of an mRNA COVID-19 vaccine or any of its components (e.g., PEG): ACIP considers this a contraindication to vaccination with the mRNA COVID-19 vaccines.13 Consideration may be given to using an alternative COVID-19 vaccine (Novavax COVID-19 vaccine) in such individuals.13
Known (diagnosed) allergy to a component of the vaccine (e.g., PEG): ACIP considers this a contraindication to vaccination with the mRNA COVID-19 vaccines.13 Consideration may be given to using an alternative COVID-19 vaccine (Novavax COVID-19 vaccine) in such individuals.13
History of any immediate allergic reaction to any other vaccine or injectable therapy (i.e., IM, IV, or sub-Q vaccines or therapies): ACIP considers this a precaution, but not a contraindication, to COVID-19 vaccination.13
History of immediate allergic reaction to a vaccine or injectable therapy that contains multiple components (one or more of which is a component of a COVID-19 vaccine), but it is not known which component elicited the reaction: ACIP considers this a precaution, but not a contraindication, to the COVID-19 vaccine.13
History of allergic reactions (including severe allergic reactions) not related to COVID-19 vaccines, other vaccines, or injectable therapies: ACIP states that food, pet, insect, venom, or environmental allergies and allergic reactions to oral medications (including the oral equivalents of injectable medications) are not a contraindication or precaution to COVID-19 vaccination.13 Latex allergy is not a contraindication or precaution since vial stoppers of COVID-19 vaccines are not made with natural rubber latex.13 Allergies to eggs or gelatin are not a contraindication or precaution since COVID-19 vaccines do not contain eggs or gelatin.13 In addition, a family history of allergies is not a contraindication or precaution to COVID-19 vaccination.13
ACIP states to observe the following individuals for 30 minutes after vaccination: those with a history of an immediate allergic reaction of any severity to any other vaccine or injectable therapy, those with a contraindication to a different type of COVID-19 vaccine (i.e., viral vector), those with a history of a non-severe, immediate allergic reaction to a previous dose of COVID-19 vaccine, and those with a history of anaphylaxis due to any cause not considered a contraindication; observe all other individuals for 15 minutes.13 Instruct vaccine recipients to seek immediate medical care if they develop signs or symptoms of an allergic reaction after their observation period ends and they have left the vaccination site.13
Appropriate medications and supplies to manage immediate allergic reactions must be immediately available in the event that an acute anaphylactic reaction occurs following administration of a COVID-19 vaccine.13
ACIP interim guidance regarding management of anaphylaxis are available at the CDC website at [Web].13
Lymphadenopathy
Lymphadenopathy, lymphadenitis, lymph node pain, injection-site lymphadenopathy, axillary swelling/tenderness, and axillary mass reported in clinical trials evaluating COVID-19 vaccine (Pfizer-BioNTech).1 3 10
Unilateral axillary adenopathy, including palpable axillary mass, identified through self-detection or incidentally on breast imaging in individuals who received an mRNA COVID-19 vaccine outside of clinical trials.30 44 Consider vaccine-induced hyperplastic axillary adenopathy in differential diagnosis if unilateral axillary adenopathy identified on breast imaging in individuals who recently received an mRNA COVID-19 vaccine.30 44
Myocarditis and Pericarditis
Rare reports of acute myocarditis or pericarditis in recipients of mRNA COVID-19 vaccines.1 3 13 53 54 55 56 57 58 Symptom onset typically within 0–7 days (range: 0–40 days) after receipt of a dose of an mRNA COVID-19 vaccine.2 53 54 57
Has occurred predominantly in males <40 years of age.13 54 55 56 58 In some cases, patients were hospitalized and responded to medications and rest with rapid improvement or resolution of symptoms.1 54 55 56 57
Consider possibility of myocarditis and pericarditis in the differential diagnosis for any individual who develops acute chest pain, shortness of breath, or palpitations after receipt of an mRNA COVID-19 vaccine.53 54 58 Consider expert consultation regarding diagnosis, management, and follow-up.53
If myocarditis or pericarditis occurs after receipt of a COVID-19 vaccine, report the case to VAERS.13
Syncope
Syncope (fainting) may occur in association with administration of injectable vaccines.1 609 Procedures should be in place to avoid injury from fainting.1 ACIP states to consider observing individuals receiving the vaccine, especially adolescents, for 15 minutes after vaccination.13
Concomitant Illness
Base decision to administer or delay vaccination in an individual with a current or recent febrile illness on the severity of symptoms and etiology of the illness.20
ACIP states that a moderate or severe acute illness is a precaution for administration of vaccines and recommends that a risk assessment be performed with potential deferral of vaccination.13 Deferring vaccination until an individual has recovered avoids superimposing adverse effects of the vaccine on the underlying illness or mistakenly concluding that a manifestation of the underlying illness resulted from vaccination.20
Data not available to date regarding safety and efficacy of COVID-19 vaccines in adults or children with a history of multisystem inflammatory syndrome.13 ACIP recommends weighing theoretical concerns about a dysregulated immune response against the known risks of COVID-19 following reinfection and the benefits of protection following COVID-19 vaccination.13
Individuals with Underlying Medical Conditions
ACIP states that individuals with altered immunocompetence or certain underlying medical conditions may receive any COVID-19 vaccine approved or authorized by FDA, unless they have a contraindication to the vaccine.13 Current FDA-approved or FDA-authorized COVID-19 vaccines are not live vaccines, so they may be safely administered to immunocompromised individuals.13
US healthcare providers and health departments can request a clinical consultation from the Clinical Immunization Safety Assessment COVIDvax project ([Web]) if they have concerns about vaccinating individuals with certain underlying medical conditions.13
Although a causal relationship not established, several cases of Bell's palsy reported in COVID-19 vaccine trials.1
Advise individuals who have bleeding disorders or are receiving anticoagulant therapy about the risk of hematoma from IM injections.20
Specific Populations
Pregnancy
Data insufficient to date to inform vaccine-associated risks during pregnancy.1
Developmental toxicity studies in rats did not reveal evidence of vaccine-related adverse effects on female fertility, fetal development, or postnatal development.1
Available data suggest that, while absolute risk is low, pregnant women with COVID-19 are at increased risk of severe illness, preterm birth and possibly increased risk of adverse pregnancy complications and outcomes.13 16 34
FDA states pregnancy is not a contraindication to use of the Pfizer-BioNTech COVID-19 vaccine; pregnant women should discuss potential benefits and risks of vaccination with their healthcare providers.19
ACIP states vaccination against COVID-19 is recommended for pregnant women.13 Evidence indicates that benefits of vaccination against COVID-19 during pregnancy outweigh any known or potential risks.13
ACOG recommends that pregnant women be vaccinated against COVID-19.16 ACOG suggests that clinicians review available data on risks and benefits of vaccination, including risks of not getting vaccinated, in the context of the individual's current health status and risk of exposure.16
Encourage women who receive a COVID-19 vaccine during pregnancy and those who become pregnant within 30 days after receiving a COVID-19 vaccine to participate in CDC's v-safe program.16
Lactation
Not known whether Pfizer-BioNTech COVID-19 vaccine is distributed into milk.1 Data not available to assess whether the vaccine administered to a woman who is breast-feeding has any effects on breast-fed infant or milk production.1 FDA states that breast-feeding is not a contraindication to use of the Pfizer-BioNTech COVID-19 vaccine; breast-feeding women should discuss benefits and risks of vaccination with their healthcare providers.19
ACIP states that vaccination against COVID-19 recommended for lactating women.13 FDA-authorized COVID-19 vaccines administered to breast-feeding women cannot cause SARS-CoV-2 infection in women or their infants; therefore, breast-feeding women can receive COVID-19 vaccination.13
ACOG recommends that lactating women be vaccinated against COVID-19.16 ACOG also states that theoretical concerns regarding safety of vaccinating lactating women do not outweigh potential benefits of the vaccine; there is no need for individuals who receive a COVID-19 vaccine to avoid initiating breast-feeding or to discontinue breast-feeding.16
Females and Males of Reproductive Potential
ACIP recommends vaccination against COVID-19 in women currently trying to become pregnant and those who might become pregnant in the future.13 Women trying to become pregnant do not need to avoid pregnancy after COVID-19 vaccination.13 There is no evidence that any FDA-approved or FDA-authorized COVID-19 vaccines affect current or future fertility.13
ACOG recommends vaccination for all eligible individuals, including those who may consider future pregnancy.16
Pediatric Use
Pfizer-BioNTech COVID-19 vaccine, mRNA (2023-2024 Formula) is authorized for use in children 6 months through 11 years of age.609
The Comirnaty COVID-19 vaccine (2023-2024 Formula) is FDA-labeled for use in adolescents ≥12 years of age.1
Geriatric Use
Individuals ≥65 years of age have been included in clinical trials evaluating the original Pfizer-BioNTech COVID-19 monovalent vaccine (no longer authorized for use in the US), and data from such individuals contribute to the overall assessment of safety and efficacy of the vaccine.1
Common Adverse Effects
Most common adverse reactions (≥10%) after a dose of COMIRNATY: pain at the injection site, fatigue, headache, chills, muscle pain, joint pain, fever, injection site swelling, injection site redness.1
Solicited adverse effects in individuals 6 months through 23 months of age receiving the COVID-19 vaccine, mRNA (Pfizer-BioNTech): Injection site redness, swelling and tenderness, decreased appetite drowsiness, fever, irritability.609
Solicited adverse effects in individuals 2 through 11 years of age receiving the COVID-19 vaccine, mRNA (Pfizer-BioNTech): Injection site pain, redness and swelling, chills, diarrhea, fatigue, fever, headache, new or worsened joint pain, new or worsened muscle pain, vomiting.609
Drug Interactions
Vaccines
Data not available to date to assess safety and immunogenicity of concomitant administration of COVID-19 vaccine (Pfizer-BioNTech) with other vaccines.1 13 Immunogenicity and adverse event profiles are generally similar whether vaccines are administered concomitantly or alone.13 Base decisions to administer a COVID-19 vaccine concomitantly with other vaccine(s) on whether routine immunizations with the other vaccines have been delayed or missed, the individual's risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and reactogenicity profiles of the vaccines.13
ACIP states that COVID-19 vaccines may be administered without regard to timing of other vaccines, including simultaneous administration on the same day.13 If a COVID-19 vaccine is administered concomitantly with other vaccines, administer at a different injection site and, if possible, separate injection sites by ≥1 inch.13
Specific Drugs
Drug |
Interaction |
Comments |
---|---|---|
Antithrombotic agents |
ACIP does not recommend taking aspirin or an anticoagulant before vaccination with any currently FDA-approved or FDA-authorized COVID-19 vaccine, unless the patient is taking these drugs as part of their routine medications13 |
|
Antiviral agents |
Antiviral agents given at any interval before or after COVID-19 vaccination unlikely to impair development of vaccine-induced protective antibody responses13 |
|
Immune globulin and antibody therapies not specific for SARS-CoV-2 (e.g., immune globulin IV [IGIV], Rho[D] immune globulin) |
May give COVID-19 vaccine concurrently with or at any interval before or after immune globulin or antibody therapies not specific for SARS-CoV-2; ACIP states there is no recommended minimum interval between receipt of antibody therapies not specific for SARS-CoV-2 and COVID-19 vaccination13 |
|
Immunosuppressive agents (e.g., cancer chemotherapy, corticosteroids, radiation) |
Possible decreased or suboptimal antibody responses to vaccines, including the Pfizer-BioNTech COVID-19 vaccine1 13 20 Data insufficient to date to inform optimal timing of COVID-19 vaccination for individuals planning to receive immunosuppressive therapies13 |
ACIP states that individuals receiving immunosuppressive therapy may receive COVID-19 vaccination if they have no contraindications to the vaccine13 |
Stability
Storage
Suspension for Injection
Consult prescribing information or EUA fact sheet for information on storage, handling, and stability of the vaccine.1 609 Various documents that describe the shipping, storage, and handling requirements and procedures for the Pfizer-BioNTech COVID-19 vaccine, including specifics about temperature requirements and temperature monitoring, thermal shipping containers, ultra-low-temperature freezers, and safe handling of dry ice, are available at [Web].
Actions
-
Nucleoside-modified mRNA (modRNA) vaccine formulated in lipid nanoparticles (LNPs).1 3 6 7 10 11
-
The modRNA contained in the Pfizer-BioNTech COVID-19 vaccine encodes a membrane-anchored, full-length spike (S) glycoprotein receptor-binding domain (RBD) antigen of SARS-CoV-2 with 2 proline modifications that lock the S protein in an antigenically preferred prefusion conformation.1 3 10 11 Following IM injection, the LNPs in the vaccine enable delivery of the modRNA into host cells where it is released and translated to the encoded S antigen of SARS-CoV-2.1 3 11 The S antigen is then incorporated into cellular membranes and elicits an immune response to provide protection against SARS-CoV-2.1 3 11
Advice to Patients
-
Advise the vaccine recipient or caregiver to read the FDA-approved patient labeling or FDA Fact Sheet.1 609
-
Inform the vaccine recipient or caregiver of the potential benefits and risks of vaccination.1 609
-
Instruct the vaccine recipient or caregiver to report any adverse events to their healthcare provider or to the Vaccine Adverse Event Reporting System at 1-800-822-7967 and www.vaers.hhs.gov.1
-
The vaccination provider must include vaccination information in the state/local jurisdiction’s Immunization Information System (IIS) or other designated system.609 Advise recipient or caregiver that more information about IISs can be found at: https://www.cdc.gov/vaccines/programs/iis/about.html.609
-
Advise patient to inform their clinician of existing or contemplated concomitant therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as any concomitant illnesses.1 609
-
Advise women to inform their clinician if they are or plan to become pregnant or plan to breast-feed.1 609
-
Inform patients of other important precautionary information.1 609
Additional Information
The American Society of Health-System Pharmacists, Inc. represents that the information provided in the accompanying monograph was formulated with a reasonable standard of care, and in conformity with professional standards in the field. Readers are advised that decisions regarding use of drugs are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and that the information contained in the monograph is provided for informational purposes only. The manufacturer’s labeling should be consulted for more detailed information. The American Society of Health-System Pharmacists, Inc. does not endorse or recommend the use of any drug. The information contained in the monograph is not a substitute for medical care.
Preparations
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
Routes |
Dosage Forms |
Strengths |
Brand Names |
Manufacturer |
---|---|---|---|---|
Parenteral |
Suspension for injection, for IM use |
3 mcg (of modRNA) per 0.3-mL dose |
Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) (available as multiple dose vials with yellow caps and labels) |
Pfizer |
10 mcg (of modRNA) per 0.3-mL dose |
Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) (available as single dose vials with blue caps and labels) |
Pfizer |
||
30 mcg (of modRNA) per 0.3-mL dose |
Comirnaty (2023-2024 Formula) (available in single dose vials and single dose prefilled syringes) |
Pfizer |
AHFS DI Essentials™. © Copyright 2024, Selected Revisions April 10, 2024. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.
References
Only references cited for selected revisions after 1984 are available electronically.
1. Pfizer. Comirnaty (COVID-19 vaccine, mRNA) suspension for injection for IM use 2023-2024 Formula. New York, NY; 2023 Sep.
2. US Food and Drug Administration. Revised letter of authorization: Emergency use authorization (EUA) for emergency use of Pfizer-BioNTech COVID-19 vaccine for the prevention of coronavirus disease 2019 (COVID-19). Reissued 2023. From FDA website. Accessed 2023 Sept 13. https://www.fda.gov/media/150386/download
3. Pfizer. Fact sheet for healthcare providers administering vaccine (vaccination providers): Emergency use authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19)– For 12 years of age or older (purple cap). 2023 Sept. From FDA website. Accessed 2023 Sept 1
4. Pfizer. Vaccine information fact sheet for recipients and caregivers about Comirnaty (COVID-19 vaccine, mRNA) and Pfizer-BioNTech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19)– For 12 years of age and older. 2023. From FDA website. Accessed 2023 Sept 14. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine#additional
5. Pfizer. A phase 1,2,3, placebo-controlled, randomized, observer-blind, dose-finding study to evaluate the safety, tolerability, immunogenicity, and efficacy of SARS-CoV-2 RNA vaccine candidates against COVID-19 in healthy individuals. Protocol C4591001. From Pfizer website. Accessed 2020 Dec 10. https://cdn.pfizer.com/pfizercom/2020-11/C4591001_Clinical_Protocol_Nov2020.pdf
6. Walsh EE, Frenck RW Jr, Falsey AR et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. 2020; 383(25):2439-50. http://www.ncbi.nlm.nih.gov/pubmed/33053279?dopt=AbstractPlus
7. Polack FP, Thomas SJ, Kitchin N et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383:2603-2615. http://www.ncbi.nlm.nih.gov/pubmed/33301246?dopt=AbstractPlus
8. Vogel AB, Kanevsky I, Che Y et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature. 2021; 592:283-289. http://www.ncbi.nlm.nih.gov/pubmed/33524990?dopt=AbstractPlus
9. US National Library of Medicine. ClinicalTrials.gov. Accessed 2021 Dec 3. https://clinicaltrials.gov
10. Vaccines and Related Biological Products Advisory Committee. Vaccines and Related Biological Products Advisory Committee meeting December 10, 2020: FDA briefing document Pfizer-BioNTech COVID-19 vaccine. Available at FDA website. https://www.fda.gov/media/144245/download
11. Vaccines and Related Biological Products Advisory Committee. Vaccines and Related Biological Products Advisory Committee meeting December 10, 2020: Pfizer-BioNTech briefing document Pfizer-BioNTech COVID-19 vaccine (BNT162, PF-07302048). Available at FDA website. https://www.fda.gov/media/144246/download
12. Dooling K, Gargano JW, Moulia D et al. Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, September 2021. MMWR Morb Mortal Wkly Rep. 2021; 70:1344-1348. http://www.ncbi.nlm.nih.gov/pubmed/34555007?dopt=AbstractPlus
13. Advisory Committee On Immunization Practices (ACIP). Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States. Updated 2024 Mar 1. From CDC website. Updates may be available at CDC website. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html
14. US Centers for Disease Control and Prevention. Vaccine storage and handling toolkit: Updated with COVID-19 vaccine storage and handling information. Addendum added 2021 Sept 29. From CDC website. Accessed 2021 Dec 3. https://www.cdc.gov/vaccines/hcp/admin/storage/toolkit/storage-handling-toolkit.pdf
15. US Centers for Disease Control and Prevention. Pfizer-BioNTech COVID-19 vaccine information. From CDC website. Updated 2021 Dec 1. Accessed 2021 Dec 3. https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/index.html
16. American College of Obstetricians and Gynecologists. COVID-19 vaccination considerations for obstetric-gynecologic care. Practice Advisory. Updated 2021 Dec 3. From ACOG website. Accessed 2021 Dec 3. Updates may be available at ACOG website. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/vaccinating-pregnant-and-lactating-patients-against-covid-19
17. US Food and Drug Administration. Emergency use authorization for an unapproved product review memorandum: Pfizer-BioNTech COVID-19 vaccine/BNT162b2. From FDA website. Accessed 2020 Dec 27. https://www.fda.gov/media/144416/download
19. US Food and Drug Administration. Pfizer-BioNTech COVID-19 vaccine frequently asked questions. From FDA website. Dated 2021 Nov 19. Accessed 2021 Dec 3. https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/pfizer-biontech-covid-19-vaccine-frequently-asked-questions
20. Kroger A, Bahta L, Hunter P. General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). From CDC website. Accessed 2021 Dec 3. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf
22. US Centers for Disease Control and Prevention. Interim considerations: preparing for the potential management of anaphylaxis after COVID-19 vaccination. From CDC website. Revised 2021 Nov 3. Accessed 2021 Dec 3. Updates may be available at CDC website. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html
23. CDC COVID-19 Response Team., Food and Drug Administration. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep. 2021; 70:46-51. http://www.ncbi.nlm.nih.gov/pubmed/33444297?dopt=AbstractPlus
24. Dooling K, Marin M, Wallace M et al. The Advisory Committee on Immunization Practices' Updated Interim Recommendation for Allocation of COVID-19 Vaccine - United States, December 2020. MMWR Morb Mortal Wkly Rep. 2021; 69:1657-1660. http://www.ncbi.nlm.nih.gov/pubmed/33382671?dopt=AbstractPlus
26. Castells MC, Phillips EJ. Maintaining Safety with SARS-CoV-2 Vaccines. N Engl J Med. 2021; 384:643-649. http://www.ncbi.nlm.nih.gov/pubmed/33378605?dopt=AbstractPlus
27. Stone CA Jr, Liu Y, Relling MV et al. Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized. J Allergy Clin Immunol Pract. 2019; 7:1533-1540.e8. http://www.ncbi.nlm.nih.gov/pubmed/30557713?dopt=AbstractPlus
28. Vaccines and Related Biological Products Advisory Committee. Vaccines and Related Biological Products Advisory Committee meeting December 17, 2020: FDA briefing document Moderna COVID-19 vaccine. Available at FDA website. https://www.fda.gov/media/144434/download
29. Shimabukuro T. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine - United States, December 21, 2020-January 10, 2021. Am J Transplant. 2021; 21:1326-1331. http://www.ncbi.nlm.nih.gov/pubmed/33641268?dopt=AbstractPlus
30. Mehta N, Sales RM, Babagbemi K et al. Unilateral axillary Adenopathy in the setting of COVID-19 vaccine. Clin Imaging. 2021; 75:12-15. http://www.ncbi.nlm.nih.gov/pubmed/33486146?dopt=AbstractPlus
31. US Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP) recommended adult immunization schedule for ages 19 years or older, United States, 2021. Updates may be available at CDC website. http://www.cdc.gov/vaccines/schedules/index.html
32. American Association for the Study of Liver Diseases. AASLD expert panel consensus statement: vaccines to prevent COVID-19 infection in patients with liver disease. 2021 Aug 30. From AASLD website. Accessed 2021 Nov 29. https://www.aasld.org/sites/default/files/2021-02/AASLD-COVID19-VaccineDocument-February2021-FINAL.pdf
33. Munavalli GG, Guthridge R, Knutsen-Larson S et al. COVID-19/SARS-CoV-2 virus spike protein-related delayed inflammatory reaction to hyaluronic acid dermal fillers: a challenging clinical conundrum in diagnosis and treatment. Arch Dermatol Res. 2021; http://www.ncbi.nlm.nih.gov/pubmed/33559733?dopt=AbstractPlus
34. Metz TD, Clifton RG, Hughes BL et al. Disease Severity and Perinatal Outcomes of Pregnant Patients With Coronavirus Disease 2019 (COVID-19). Obstet Gynecol. 2021; 137:571-580. http://www.ncbi.nlm.nih.gov/pubmed/33560778?dopt=AbstractPlus
35. US Centers for Disease Control and Prevention. Interim public health recommendations for fully vaccinated people. From CDC website. Revised 2021 Nov 19. Accessed 2021 Dec 3. Updates may be available at CDC website. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated-guidance.html
36. US Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP) recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2021. Updates may be available at CDC website. http://www.cdc.gov/vaccines/schedules/index.html
37. Blumenthal KG, Robinson LB, Camargo CA Jr et al. Acute Allergic Reactions to mRNA COVID-19 Vaccines. JAMA. 2021; 325:1562-1565. http://www.ncbi.nlm.nih.gov/pubmed/33683290?dopt=AbstractPlus
38. Blumenthal KG, Freeman EE, Saff RR et al. Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2. N Engl J Med. 2021; 384:1273-1277. http://www.ncbi.nlm.nih.gov/pubmed/33657292?dopt=AbstractPlus
39. Wallace M, Woodworth KR, Gargano JW et al. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 Years - United States, May 2021. MMWR Morb Mortal Wkly Rep. 2021; 70:749-752. http://www.ncbi.nlm.nih.gov/pubmed/34014913?dopt=AbstractPlus
40. Shimabukuro TT, Cole M, Su JR. Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021. JAMA. 2021; 325:1101-1102. http://www.ncbi.nlm.nih.gov/pubmed/33576785?dopt=AbstractPlus
41. Welsh KJ, Baumblatt J, Chege W et al. Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2021; http://www.ncbi.nlm.nih.gov/pubmed/34006408?dopt=AbstractPlus
42. Shimabukuro T, CDC COVID-19 Vaccine Task Force Vaccine Safety Team. Update: Thrombosis with thrombocytopenia syndrome (TTS) following COVID-19 vaccination. Meeting materials from Advisory Committee on Immunization Practices (ACIP) meeting May 12, 2021. Available at ACIP website. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-05-12/07-COVID-Shimabukuro-508.pdf
43. Society of Breast Imaging. SBI recommendations for the management of axillary adenopathy in patients with recent COVID-19 vaccination. Updated February 8, 2022. Accessed 2022 Sept 20. https://assets-002.noviams.com/novi-file-uploads/sbi/5-3-23_-_ACR_SBI_Statement_on_New_USPSTF_BCS_Recs.pdf
44. Keshavarz P, Yazdanpanah F, Rafiee F et al. Lymphadenopathy Following COVID-19 Vaccination: Imaging Findings Review. Acad Radiol. 2021; http://www.ncbi.nlm.nih.gov/pubmed/33985872?dopt=AbstractPlus
45. Singh B, Kaur P, Kumar V et al. COVID-19 vaccine induced Axillary and Pectoral Lymphadenopathy on PET scan. Radiol Case Rep. 2021; 16:1819-1821. http://www.ncbi.nlm.nih.gov/pubmed/33968285?dopt=AbstractPlus
46. Schroeder DG, Jang S, Johnson DR et al. Frequency and Characteristics of Nodal and Deltoid FDG and 11C-Choline Uptake on PET Imaging Performed After COVID-19 Vaccination. AJR Am J Roentgenol. 2021; http://www.ncbi.nlm.nih.gov/pubmed/34009000?dopt=AbstractPlus
47. Society of Nuclear Medicine & Molecular Imaging. SNMMI statements: the effect of COVID-19 vaccination on FDG PET/CT. 2021 Mar 30. Accessed 2021 Nov 26. https://www.snmmi.org/NewsPublications/NewsDetail.aspx?ItemNumber=36729#:~:text=Reactive%20lymphadenopathy%20has%20been%20reported,Janssen%2FJohnson%20%26%20Johnson).
48. Lehman CD, D'Alessandro HA, Mendoza DP et al. Unilateral Lymphadenopathy After COVID-19 Vaccination: A Practical Management Plan for Radiologists Across Specialties. J Am Coll Radiol. 2021; http://www.ncbi.nlm.nih.gov/pubmed/33713605?dopt=AbstractPlus
49. Shimabukuro TT, Kim SY, Myers TR et al. Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. N Engl J Med. 2021; http://www.ncbi.nlm.nih.gov/pubmed/33882218?dopt=AbstractPlus
50. Collier AY, McMahan K, Yu J et al. Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. JAMA. 2021; http://www.ncbi.nlm.nih.gov/pubmed/33983379?dopt=AbstractPlus
51. Gray KJ, Bordt EA, Atyeo C et al. Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study. Am J Obstet Gynecol. 2021; http://www.ncbi.nlm.nih.gov/pubmed/33775692?dopt=AbstractPlus
52. Frenck RW Jr, Klein NP, Kitchin N et al. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med. 2021; http://www.ncbi.nlm.nih.gov/pubmed/34043894?dopt=AbstractPlus
53. US Centers for Disease Control and Prevention. Clinical considerations: myocarditis and pericarditis after receipt of mRNA COVID-19 vaccines among adolescents and young adults. From CDC website. 2021 Nov 9. Accessed 2021 Nov 26. Updates may be available at CDC website. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html
54. Marshall M, Ferguson ID, Lewis P et al. Symptomatic Acute Myocarditis in Seven Adolescents Following Pfizer-BioNTech COVID-19 Vaccination. Pediatrics. 2021; http://www.ncbi.nlm.nih.gov/pubmed/34088762?dopt=AbstractPlus
55. Gargano JW, Wallace M, Hadler SC et al. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021. MMWR Morb Mortal Wkly Rep. 2021; 70:977-982. http://www.ncbi.nlm.nih.gov/pubmed/34237049?dopt=AbstractPlus
56. Kim HW, Jenista ER, Wendell DC et al. Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. JAMA Cardiol. 2021; http://www.ncbi.nlm.nih.gov/pubmed/34185046?dopt=AbstractPlus
57. Montgomery J, Ryan M, Engler R et al. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. JAMA Cardiol. 2021; http://www.ncbi.nlm.nih.gov/pubmed/34185045?dopt=AbstractPlus
58. Tano E, San Martin S, Girgis S et al. Perimyocarditis in Adolescents After Pfizer-BioNTech COVID-19 Vaccine. J Pediatric Infect Dis Soc. 2021; http://www.ncbi.nlm.nih.gov/pubmed/34319393?dopt=AbstractPlus
59. Kamar N, Abravanel F, Marion O et al. Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. N Engl J Med. 2021; 385:661-662. http://www.ncbi.nlm.nih.gov/pubmed/34161700?dopt=AbstractPlus
60. Hall VG, Ferreira VH, Ierullo M et al. Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients. Am J Transplant. 2021; http://www.ncbi.nlm.nih.gov/pubmed/34347934?dopt=AbstractPlus
61. Hall VG, Ferreira VH, Ku T et al. Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients. N Engl J Med. 2021; http://www.ncbi.nlm.nih.gov/pubmed/34379917?dopt=AbstractPlus
62. Crombie JL, Sherman AC, Cheng CA et al. Activity of mRNA COVID-19 vaccines in patients with lymphoid malignancies. Blood Adv. 2021; 5:3062-3065. http://www.ncbi.nlm.nih.gov/pubmed/34387646?dopt=AbstractPlus
63. Perry C, Luttwak E, Balaban R et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Adv. 2021; 5:3053-3061. http://www.ncbi.nlm.nih.gov/pubmed/34387648?dopt=AbstractPlus
64. Schramm R, Costard-Jäckle A, Rivinius R et al. Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients. Clin Res Cardiol. 2021; 110:1142-1149. http://www.ncbi.nlm.nih.gov/pubmed/34241676?dopt=AbstractPlus
65. Narasimhan M, Mahimainathan L, Clark AE et al. Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA Vaccines. Vaccines (Basel). 2021; 9 http://www.ncbi.nlm.nih.gov/pubmed/34208884?dopt=AbstractPlus
66. Study to describe safety, tolerability, immunogenicity, and efficacy of RNA vaccine candidates against COVID-19 in healthy individuals. NCT04368728. Update posted 2021 May 4. https://www.clinicaltrials.gov/ct2/show/study/NCT04368728
67. US Food and Drug Administration. Questions and answers for Comirnaty (COVID-19 vaccine mRNA). From FDA website. Dated 2021 Oct 20. Accessed 2021 Dec 3. https://www.fda.gov/vaccines-blood-biologics/qa-comirnaty-covid-19-vaccine-mrna
68. US Food and Drug Administration. Summary basis for regulatory action. BioNTech Manufacturing GmBH (in partnership with Pfizer, Inc) COVID-19 vaccine mRNA. 2021 Aug 23. From FDA website. https://www.fda.gov/media/151733/download
69. Vaccines and Related Biological Products Advisory Committee. Vaccines and Related Biological Products Advisory Committee meeting September 17, 2021: FDA briefing document application for licensure of a booster dose fo Comirnaty (COVID-19 vaccine, mRNA). Available at FDA website. https://www.fda.gov/media/152176/download
70. Fact sheet for healthcare providers administering vaccine (vaccination providers): Emergency use authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19) – For 5 through 11 years of age (orange cap). 2022 Oct 12. From FDA website. Accessed 2022 Oct 30 https://www.fda.gov/media/153714/download
72. US Centers for Disease Control and Prevention. Emergency Use Instructions for Healthcare Providers: Pfizer-BioNTech COVID-19 vaccine for Additional Primary and Booster Doses in Certain Persons Who Completed Primary Vaccination with Vaccines Not Approved/Authorized in the United States. From CDC website. Issued 2021 Nov 17. Accessed 2022 Jan 11. Updates may be available at CDC website https://www.cdc.gov/vaccines/covid-19/eui/downloads/EUI-HCP.pdf
73. Pfizer. Fact sheet for healthcare providers administering vaccine (vaccination providers): Emergency use authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19) – For 12 years of age or older (gray cap). 2022 Aug 31. From FDA website. Accessed 2022 Oct 30. https://www.fda.gov/media/153715/download
80. Mbaeyi S, Oliver SE, Collins JP et al. The Advisory Committee on Immunization Practices' Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines - United States, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70:1545-1552. http://www.ncbi.nlm.nih.gov/pubmed/34735422?dopt=AbstractPlus
81. US Centers for Disease Control and Prevention. Science brief: COVID-19 vaccines and vaccination. From CDC website. Updated 2021 Sept 15. Accessed 2021 Nov 29. Updates may be available at CDC website. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/fully-vaccinated-people.html#:~:text=Multiple%20studies%20from%20the%20United,sequelae%20including%20severe%20disease%2C%20hospitalization
84. Pfizer. Fact sheet for healthcare providers administering vaccine (vaccination providers): Emergency use authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19) – For 6 months through 5 years (maroon cap). 2022 Aug 31. From FDA website. Accessed 2022 Aug 31. https://www.fda.gov/media/159312/download
96. Pfizer. Fact sheet for healthcare providers administering vaccine: Emergency use authorization (EUA) of Pfizer-BioNTech COVID-19 vaccine, bivalent (original and omicron BA.4/BA.5). 2023. From FDA website. Accessed 2022 Oct 30. https://www.fda.gov/media/167211/download
97. Pfizer. Fact sheet for healthcare providers administering vaccine (vaccination providers): Emergency use authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine, bivalent to prevent coronavirus disease 2019 (COVID-19) – Booster dose for 5 through 11 years of age (orage cap and border). 2022 Oct 12. From FDA website. Accessed 2022 Oct 30. https://www.fda.gov/media/162250/download
500. FDA press release. Coronavirus (COVID-19) Update: FDA Authorizes Changes to Simplify Use of Bivalent mRNA COVID-19 Vaccines (issued April 18, 2023) https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-changes-simplify-use-bivalent-mrna-covid-19-vaccines
600. The National Alert Network (NAN). Mix-ups between the influenza (flu) vaccine and COVID-19 vaccines. Available from the NAN website. https://www.ismp.org/sites/default/files/attachments/2021-10/NAN-20211015.pdf
605. The National Alert Network (NAN). Age-related COVID-19 vaccine mix-ups between the influenza (flu) vaccine and COVID-19 vaccines. Available from the NAN website. https://www.ismp.org/sites/default/files/attachments/2021-12/NAN-20211206.pdf
606. US Food and Drug Administration. Recommendation for the 2023-2024 Formula of COVID-19 vaccines in the U.S. https://www.fda.gov/media/169591/download. Accessed Sept 15, 2023.
607. World Health Organization. EG.5 Initial Risk Evaluation, 9 August 2023. https://www.who.int/docs/default-source/coronaviruse/09082023eg.5_ire_final.pdf?sfvrsn=2aa2daee_1
608. Food and Drug Administration (FDA)Center for Biologics Evaluation and Research (CBER). 182nd Meeting of the Vaccines and Related Biological Products Advisory Committee (VRBPAC). June 15, 2023. https://www.fda.gov/media/169804/download
609. Pfizer. Fact sheet for healthcare providers administering vaccine: Emergency use authorization (EUA) of Pfizer-BioNTech COVID-19 vaccine (2023-2024 Formula for 6 months through 11 years of age). From FDA website. Accessed 2023 Sept 14 https://www.fda.gov/media/167211/download
610. Wolfson S, Kim E, Plaunova A, et al. Axillary Adenopathy after COVID-19 Vaccine: No reason to delay screening mammogram. Radiology 2022; 303:297-99.
Frequently asked questions
More about sars-cov-2 mrna (tozinameran) vaccine
- Check interactions
- Compare alternatives
- Reviews (17)
- Latest FDA alerts (1)
- Side effects
- Dosage information
- During pregnancy
- Drug class: viral vaccines
Professional resources
- Covid-19 Vaccine Pfizer prescribing information
- Covid-19 Vaccine Pfizer, Monovalent, 6 mo-4 yr (FDA)
- Covid-19 Vaccine Pfizer, Monovalent,5 yr to 11 yr (FDA)
- Pfizer-BioNTech Vaccine (FDA)